logo-loader
viewArix Bioscience PLC

Jefferies puts 229p target on Arix Bioscience

“The current 31% discount is cheap in our view and allows no value for Arix's private assets,” the broker said

Arix Bioscience PLC - Jefferies puts 229p target on Arix Bioscience
The "buy" recommendation was reiterated

Arix Bioscience PLC (LON:ARIX) should attract more investor interest after its capital market day, according to analysts at Jefferies.

The venture capital company, which invests in disruptive growth companies, reiterated the “buy” recommendation and set the price target at 229p.

“The current 31% discount is cheap in our view and allows no value for Arix's private assets,” the broker said in a note on Monday.

 Shares were up 1.82% to 112p in afternoon trade.

Quick facts: Arix Bioscience PLC

Price: 111.5 GBX

LSE:ARIX
Market: LSE
Market Cap: £151.14 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Arix Bioscience PLC named herein, including the promotion by the Company of Arix Bioscience PLC in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Arix Bioscience acquires stake in novel firm developing sickle cell treatment

Arix Bioscience PLC (LON:ARIX) investment associate John Cassidy talks Proactive London through its decision to invest US$15mln (£11.3mln) in Imara - a firm which is developing treatments for sickle cell disease. Through the deal Arix receives a 10% stake in the company while also...

on 19/3/19

2 min read